Ayse Cefle
Kocaeli University
148 Papers
272 Citations
Ayse Cefle is an academic researcher from Kocaeli University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 96 publications. Previous affiliations of Ayse Cefle include Eskişehir Osmangazi University & Istanbul University.
Chat about Author
Papers
Behçet disease with vascular involvement: effects of different therapeutic regimens on the incidence of new relapses.
Fatma Alibaz-Oner,Asl Karadeniz,Sema Ylmaz,Ayşe Balkarl,Gezmiş Kimyon,Ayten Yazc,Muhammet Çnar,Sedat Ylmaz,Fatih Yldz,Şule Yaşar Bilge,Emre Bilgin,Belkıs Nihan Coşkun,Ahmet Omma,Gözde Yldrm Çetin,Yonca Cagatay,Yaşar Karaaslan,Mehmet Sayarloğlu,Yavuz Pehlivan,Umut Kalyoncu,Omer Karadag,Timuçin Kaşifoğlu,Eren Erken,Salih Pay,Ayse Cefle,Bünyamin Ksack,Ahmet Mesut Onat,Veli Cobankara,Haner Direskeneli +27 more
TL;DR: It is suggested that short duration of IS treatments and compliance issues of treatment are the major problems in VBD associated with vascular relapses during follow-up.
143
Risk factors for avascular bone necrosis in patients with systemic lupus erythematosus
Mehmet Sayarlioglu,Nergis Yuzbasioglu,Murat Inanc,Sevil Kamali,Ayse Cefle,Özcan Karaman,Ahmet Mesut Onat,Rustem Avan,Gözde Çetin,Ahmet Gül,Lale Ocal,Orhan Aral +11 more
TL;DR: The highest dose corticosteroid administered within 4 months and total cumulative prednisolone dose were significantly higher in the SLE patients with AVN, and the use of cytotoxic agent significantly higher proportion of patients withAVN.
82
Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease: Data from a large multicenter cohort.
Umut Kalyoncu,Dilek Solmaz,Hakan Emmungil,Ayten Yazici,Timuçin Kaşifoğlu,Gezmiş Kimyon,Ayse Balkarli,Cemal Bes,Mustafa Özmen,Fatma Alibaz-Oner,Şükran Erten,Yonca Cagatay,Gozde Yildirim Cetin,Sedat Yilmaz,Fatih Yildiz,Ömer Nuri Pamuk,Orhan Küçükşahin,Levent Kilic,Veli Yazisiz,Omer Karadag,Süleyman Serdar Koca,Mutlu Hayran,Servet Akar,Kenan Aksu,Nurullah Akkoc,Gökhan Keser,Emel Gönüllü,Bunyamin Kisacik,Ahmet Mesut Onat,Mehmet Soy,Nevsun Inanc,Haner Direskeneli,Mehmet Sayarlioglu,Eren Erken,Murat Turgay,Ayse Cefle,Ihsan Ertenli,Salih Pay +37 more
TL;DR: The multivariate analysis revealed that the male sex, delayed diagnosis of more than 6 months, failure to achieve remission with initial treatment, and arthritis involving wrist/elbow joints were related to the chronic disease course in AOSD.
80
Impaired quality of life, disability and mental health in Takayasu’s arteritis
Neslihan Yilmaz,Meryem Can,Fatma Alibaz Öner,Melike Kalfa,Hakan Emmungil,Omer Karadag,Fatih Yildiz,Gezmiş Kimyon,Baris Yilmazer,Vedat Gerdan,Şule Yaşar Bilge,Birkan Ilhan,Veli Cobankara,Timuçin Kaşifoğlu,Ayse Cefle,B. Kisacik,Ahmet Mesut Onat,Servet Akar,Fatos Onen,Eren Erken,Sedat Kiraz,Kenan Aksu,Gökhan Keser,Gonca Mumcu,Haner Direskeneli +24 more
TL;DR: The results, especially in active disease, suggest that PROs such as SF-36 can be core domains of disease assessment in TAK, similar to ANCA-associated vasculitides.
Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases.
Neslihan Yilmaz,Hakan Emmungil,Sercan Gücenmez,Gulsen Ozen,Fatih Yildiz,Ayse Balkarli,Gezmiş Kimyon,Belkıs Nihan Coşkun,İsmail Doğan,O.N. Pamuk,Sule Yasar,Gozde Yildirim Cetin,Ayten Yazici,Serpil Ergulu Esmen,Yonca Cagatay,Sema Yilmaz,Ayse Cefle,Mehmet Sayarlioglu,Timuçin Kaşifoğlu,Omer Karadag,Yavuz Pehlivan,Ediz Dalkilic,Bunyamin Kisacik,Veli Cobankara,Eren Erken,Haner Direskeneli,Kenan Aksu,Sule Yavuz +27 more
TL;DR: C Cumulative dose was the only risk factor for hemorrhagic cystitis in patients treated with CYC and no proof was obtained for the uroprotective effect of mesna in the authors' cohort.
55